Page 7 - Pooled Analysis News Today

Poster presentations highlighting safety and preliminary efficacy data of epcoritamab (DuoBody-CD3xCD20) in combination with other treatments in patients with B-cell non-Hodgkin lymphoma (NHL)

Numerous oral presentations highlighting data for tafasitamab, parsaclisib, ruxolitinib, pemigatinib, itacitinib and ponatinib to be highlighted during the Congress Incyte (Nasdaq:INCY) today announced

Research to be presented on Orencia, deucravacitinib and pipeline assets highlights breadth of data and focus on transforming treatment paradigms for people living with rheumatic diseases Bristol Myers Squibb today announced data from 29 company-sponsored presentations across Orencia, deucravacitinib and pipeline assets will be presented at the American College of Rheumatology Convergence 2021, taking place ...

Consensus REACHED: An Astounding 91 Clinical Research Studies ALL CONFIRMED That NATURAL IMMUNITY Provides Same, If Not Better Protection Against the

/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the presentation of...

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year ef...

RedHill Biopharma Presents Analyses of Movantik Onset of Action and Symptom Improvement at DDW 2021 USA - English Two new analyses of Movantik® (naloxegol) data, from almost 900 patients, were presented at Digestive Disease Week 2021 evaluating the onset of action and symptom improvement of Movantik for a broad range of challenging opioid-induced constipation (OIC) symptoms Movantik is an oral peripherally acting mu-opioid receptor antagonist (PAMORA) approved in the U.S. to treat OIC in adult...

Bristol Myers Squibb (NYSE:BMY) today announced that additional data from multiple studies evaluating Zeposia (ozanimod) in ulcerative colitis (UC) were presented at Digestive Disease Week ® (DDW), taking place virtually May 21-23, 2021. These data deepen the understanding of Zeposia and reinforce Bristol Myers Squibb’s commitment to understanding and addressing unmet needs in gastroenterology. Research being shared includes: Safety of Ozanimod in Patients with Moderately to Severely ...

Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool Mayo Clinic and AMC Amsterdam to Present Data on Predicting Progression to Esophageal Cancer in Barrett’s Esophagus May 17, 2021 08:38 ET | Source: Cernostics Cernostics Pittsburgh, Pennsylvania, UNITED STATES PITTSBURGH, Pennsylvania, May 17, 2021 – Cernostics ( cernostics.com/) a pioneer in delivering spatialomi...

Intra-Cellular Therapies Announces Investor Webcast and Presentations on Lumateperone Programs at the Upcoming American Psychiatric Association (APA) Annual Meeting April 22, 2021 07:30 ET | Source: Intra-Cellular Therapies Inc. Intra-Cellular Therapies Inc. Webcast to be Held Tuesday, May 4, 2021 at 2:00 p.m. EDT Webcast Will Feature Key Opinion Leader, Dr. Roger McIntyre, Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disord...